CBDA
Cannabidiolic Acid
Cannabidiolic acid (CBDA) is the acidic precursor to CBD found abundantly in raw, unprocessed cannabis and hemp. It converts to CBD through decarboxylation (heat). Emerging research suggests CBDA may be more potent than CBD for nausea, anxiety, and inflammation at lower doses.
Quick Facts
- Molecular Formula
- C₂₂H₃₀O₄
- Molecular Weight
- 358.47 g/mol
- Boiling Point
- ~120°C (248°F) — decarboxylates to CBD
- Legal Status (U.S.)
- CBDA derived from hemp (≤0
- Research Status
- Emerging preclinical evidence
About CBDA
Cannabidiolic acid (CBDA) is the biosynthetic precursor to CBD. In living cannabis plants, CBDA is the dominant form — CBD itself is present only in trace amounts until the plant material is heated (decarboxylated) above approximately 120°C. CBDA is produced from CBGA (cannabigerolic acid) via the enzyme CBDA synthase.
CBDA was long considered pharmacologically inert, but research over the past decade has revealed a distinct and potent mechanism of action. CBDA is a highly selective and potent agonist of the 5-HT1A serotonin receptor — with affinity approximately 100-fold greater than CBD itself. This makes it particularly relevant to nausea, vomiting, and anxiety. A 2013 British Journal of Pharmacology study demonstrated CBDA's superior anti-nausea effects compared to CBD in animal models of anticipatory nausea.
CBDA also inhibits COX-2 (cyclooxygenase-2) enzymes, the same target as NSAIDs like ibuprofen, suggesting anti-inflammatory potential. Unlike NSAIDs, CBDA does not inhibit COX-1, which may mean a more favorable GI safety profile — though human trials are lacking.
A key challenge with CBDA is its instability. It readily decarboxylates to CBD at room temperature over time, and is rapidly converted by heat, light, or prolonged storage. This makes standardized dosing difficult. Pharmaceutical interest has focused on more stable CBDA methyl ester derivatives (e.g., EPM301, developed by EPM Group), which showed promise in preclinical models of inflammatory bowel disease and COVID-19-related inflammation.
Clinical evidence remains limited to preclinical and early-phase studies. No CBDA-specific products have received FDA approval. Consumer products labeled as "raw" or "full-spectrum" may contain CBDA, but concentrations are rarely standardized.
Receptor Affinity
- 5-HT1A potent agonist (~100× more potent than CBD)
- COX-2 inhibitor
- TRPA1 agonist
- GPR55 antagonist
Key Mechanisms
- Potent 5-HT1A serotonin receptor agonism — primary mechanism for anti-nausea and anxiolytic effects
- COX-2 inhibition — anti-inflammatory pathway similar to NSAIDs, without COX-1 inhibition
- TRPA1 activation — contributes to pain modulation
- Decarboxylates to CBD upon heating, losing CBDA-specific receptor activity
Clinical Uses & Evidence
Graded using a modified GRADE framework. Grade A = strong evidence; B = moderate; C = preliminary.
Nausea & Vomiting
Grade CPreclinical studies show CBDA reduces anticipatory nausea more effectively than CBD via 5-HT1A agonism. No human RCTs completed.
Key study: Rock et al., British Journal of Pharmacology, 2013
Anxiety
Grade CAnimal models demonstrate anxiolytic effects at doses lower than CBD. 5-HT1A agonism is the proposed mechanism. Human data absent.
Key study: Bolognini et al., Psychopharmacology, 2013
Inflammation
Grade CCOX-2 inhibition in vitro and in animal models. Stable CBDA derivatives (EPM301) showed efficacy in IBD models. No human trials.
Key study: Takeda et al., Drug Metabolism and Disposition, 2008
Side Effects
Drug Interactions
5-HT1A agonism may potentiate serotonergic effects
Additive COX-2 inhibition may increase anti-inflammatory effect or GI risk
Always consult a pharmacist or physician before combining cannabis with prescription medications. This list is not exhaustive.
Dosing Notes
No established human dosing. Preclinical studies suggest CBDA may be effective at lower doses than CBD due to higher 5-HT1A affinity. Stability is a major challenge — products should be stored cold and away from light. Decarboxylation during cooking or vaporization converts CBDA to CBD.
Dosing information is for educational purposes only. Consult a licensed healthcare provider for personalized guidance.
Legal Status
CBDA derived from hemp (≤0.3% THC) is federally legal in the U.S. under the 2018 Farm Bill. It is not a scheduled substance. Regulatory status of CBDA-specific products is evolving.
Key Sources
- Cannabidiolic acid (CBDA): a summary of preclinical studies evaluating its anti-nausea properties. British Journal of Pharmacology, 2013.
- Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats. British Journal of Pharmacology, 2012.
- Inhibition of COX-2 activity by CBDA. Drug Metabolism and Disposition, 2008.